Michel Vounatsos, Biogen CEO (World Economic Forum/Ciaran McCrickard)

Bio­gen vows to fight CM­S' draft cov­er­age de­ci­sion for Aduhelm be­fore April fi­nal­iza­tion

Bio­gen ex­ec­u­tives made clear in an in­vestor call Thurs­day they are not prepar­ing to run a new CMS-ap­proved clin­i­cal tri­al for their con­tro­ver­sial Alzheimer’s drug …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.